*NO COVER LETTER

9803755-0

RTMP COPY

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/395, C07D 413/14 — A1

(11) International Publication Number: WO 97/18809

(43) International Publication Date: 29 May 1997 (29.05.97)

(21) International Application Number: PCT/US96/18512

(22) International Filing Date: 18 November 1996 (18.11.96)

(30) Priority Data:
60/006,970 20 November 1995 (20.11.95) US

(71) Applicant *(for all designated States except US)*: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: ENGEL, Gary, L. [US/US]; 1984 Inverness Place, Greenwood, IN 46143 (US). FARID, Nagy, A. [US/US]; 810 Millerwood Drive, Lebanon, IN 46052 (US). FAUL, Margaret, M. [IE/US]; 240 Governors Lane, Zionsville, IN 46077 (US). JIROUSEK, Michael, R. [US/US]; 10342 Fawn Ridge Lane, Indianapolis, IN 46236 (US). RICHARDSON, Lori, A. [US/US]; 4018 Pineview Circle, Indianapolis, IN 46237 (US). WINNEROSKI, Leonard, L., Jr. [US/US]; 557 Covered Bridge Road, Greenwood, IN 46142 (US).

(74) Agents: CALTRIDER, Steven, P. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).


(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: PROTEIN KINASE C INHIBITOR

(57) Abstract

This invention provides novel bis-indolylmaleimide macrocycle derivatives of formula (Ia), and solvates thereof. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.



(Ia)